

Highlights of This Issue 2193

SPECIAL FEATURES

CCR 20th Anniversary Commentary

- 2195** CCR 20th Anniversary Commentary: Expanding the Epigenetic Therapeutic Portfolio
Susan E. Bates, Robert W. Robey, and Richard L. Piekarz

- 2198** CCR 20th Anniversary Commentary: Vorinostat—Gateway to Epigenetic Therapy
Wm. Kevin Kelly, Paul Marks, and Victoria M. Richon

CCR Translations

- 2201** A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2
Yanping Xiao and Gordon J. Freeman
See related article, p. 2359

- 2204** Diffuse Large B-cell Lymphoma Classification Tied Up Nicely with a "String"
Lisa M. Rimsza
See related article, p. 2367

Molecular Pathways


- 2207** Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells
Hiba Ahmad Zahreddine and Katherine L.B. Borden

CCR Focus

- 2212** Quit Early, Quit Often
Susan E. Bates

- 2213** Lung Cancer in the Era of Precision Medicine
Katerina Politi and Roy S. Herbst

- 2221** EGFR: The Paradigm of an Oncogene-Driven Lung Cancer
Gregory J. Riely and Helena A. Yu

- 2227** Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine
 Ryohei Katayama, Christine M. Lovly, and Alice T. Shaw

- 2236** Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics
David R. Gandara, Peter S. Hammerman, Martin L. Sos, Primo N. Lara Jr, and Fred R. Hirsch

- 2244** Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?
M. Catherine Pietanza, Lauren Averett Byers, John D. Minna, and Charles M. Rudin

- 2256** Immune Checkpoint Modulation for Non-Small Cell Lung Cancer
Jean-Charles Soria, Aurélien Marabelle, Julie R. Brahmer, and Scott Gettinger

Special Report

- 2263** Accelerating the Delivery of Patient-Centered, High-Quality Cancer Care
Edward Abrahams, Margaret Foti, and Marcia A. Kean

CANCER THERAPY: CLINICAL

- 2268** Adoptive Transfer of MAGE-A4 T-cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer
Shinichi Kageyama, Hiroaki Ikeda, Yoshihiro Miyahara, Naoko Imai, Mikiya Ishihara, Kanako Saito, Sahoko Sugino, Shugo Ueda, Takeshi Ishikawa, Satoshi Kokura, Hiroaki Naota, Kohshi Ohishi, Taizo Shiraishi, Naoki Inoue, Masashige Tanabe, Tomohide Kidokoro, Hirofumi Yoshioka, Daisuke Tomura, Ikuei Nukaya, Junichi Mineno, Kazutoh Takesako, Naoyuki Katayama, and Hiroshi Shiku

- 2278** Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
Ling Zhang, Richard A. Morgan, Joal D. Beane, Zhili Zheng, Mark E. Dudley, Sadik H. Kassim, Azam V. Nahvi, Lien T. Ngo, Richard M. Sherry, Giao Q. Phan, Marybeth S. Hughes, Udai S. Kammula, Steven A. Feldman, Mary Ann Toomey, Sid P. Kerkar, Nicholas P. Restifo, James C. Yang, and Steven A. Rosenberg

Table of Contents

2289 Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition

Richard D. Carvajal, Donald P. Lawrence, Jeffrey S. Weber, Thomas F. Gajewski, Rene Gonzalez, Jose Lutzky, Steven J. O'Day, Omid Hamid, Jedd D. Wolchok, Paul B. Chapman, Ryan J. Sullivan, Jerrold B. Teitcher, Nikhil Ramaiya, Anita Giobbie-Hurder, Cristina R. Antonescu, Michael C. Heinrich, Boris C. Bastian, Christopher L. Corless, Jonathan A. Fletcher, and F. Stephen Hodi

2297 The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation

Martijn P. Lolkema, Hilde H. Bohets, Hendrik-Tobias Arkenau, Ann Lampo, Erio Barale, Maja J.A. de Jonge, Leni van Doorn, Peter Helleman, Johann S. de Bono, and Ferry A.L.M. Eskens

2305 Targeted T-cell Therapy in Stage IV Breast Cancer: A Phase I Clinical Trial

Lawrence G. Lum, Archana Thakur, Zaid Al-Kadhimi, Gerald A. Colvin, Francis J. Cummings, Robert D. Legare, Don S. Dizon, Nicola Kouttab, Abby Maizel, William Colaiaice, Qin Liu, and Ritesh Rathore

PERSONALIZED MEDICINE AND IMAGING

2315 Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

Arun A. Azad, Stanislav V. Volik, Alexander W. Wyatt, Anne Haegert, Stephane Le Bihan, Robert H. Bell, Shawn A. Anderson, Brian McConeghy, Robert Shukin, Jenny Bazov, Jack Youngren, Pamela Paris, George Thomas, Eric J. Small, Yuzhuo Wang, Martin E. Gleave, Colin C. Collins, and Kim N. Chi

CANCER THERAPY: PRECLINICAL

2325 Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms

Michele Cioffi, Sara Trabulo, Manuel Hidalgo, Eithne Costello, William Greenhalf, Mert Erkan, Joerg Kleeff, Bruno Sainz Jr, and Christopher Heeschen

2338 Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation

Masanori Hasegawa, Raj Kumar Sinha, Manoj Kumar, Maroof Alam, Li Yin, Deepak Raina, Akriti Kharbanda, Govind Panchamoorthy, Dikshi Gupta, Harpal Singh, Surender Kharbanda, and Donald Kufe

2348 Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL

Matthew C. Stubbs, Wonil Kim, Megan Bariteau, Tina Davis, Sridhar Vempati, Janna Minehart, Matthew Witkin, Jun Qi, Andrei V. Krivtsov, James E. Bradner, Andrew L. Kung, and Scott A. Armstrong

BIOLOGY OF HUMAN TUMORS

2359 Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein

Murali Janakiram, Jordan M. Chinai, Susan Fineberg, Andras Fiser, Cristina Montagna, Ramadevi Medavarapu, Ekaterina Castano, Hyungjun Jeon, Kim C. Ohaegbulam, Ruihua Zhao, Aimin Zhao, Steven C. Almo, Joseph A. Sparano, and Xingxing Zang
See related commentary, p. 2201

2367 Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System

Margaret H. Veldman-Jones, Zhongwu Lai, Mark Wappett, Chris G. Harbron, J. Carl Barrett, Elizabeth A. Harrington, and Kenneth S. Thress
See related commentary, p. 2204

2379 Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer

Ahnah Song, Tae Min Kim, Dong-Wan Kim, Soyeon Kim, Bhumsuk Keam, Se-Hoon Lee, and Dae Seog Heo

2388 Expression of Hedgehog Pathway Mediator *GLI* Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects

Jasmin Wellbrock, Emily Latuske, Julian Köhler, Katharina Wagner, Hauke Stamm, Eik Vettorazzi, Gabi Vohwinkel, Marianne Klokow, Roswitha Uibelesen, Patrick Ehm, Kristoffer Riecken, Sonja Loges, Felicitas Thol, Claudia Schubert, Michael Amling, Manfred Jücker, Carsten Bokemeyer, Michael Heuser, Jürgen Krauter, and Walter Fiedler

2399 miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma

Yijun Yang, Fei Li, Manujendra N. Saha, Jahangir Abdi, Lugui Qiu, and Hong Chang

CORRECTION

2412 Correction: Ceritinib for the Treatment of Late-Stage (Metastatic) Non-Small Cell Lung Cancer


 CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

The cover shows a section of a bone marrow biopsy from a patient with acute myeloid leukemia (AML). Immunohistochemical staining shows Desert Hedgehog positive osteoblasts underlining the hypothesis of paracrine Hedgehog pathway activation in AML cells. For details, see the article by Wellbrock and colleagues on page 2388 of this issue.



Clinical Cancer Research

21 (10)

Clin Cancer Res 2015;21:2193-2412.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/21/10>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/21/10>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.